- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03933488
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is called TAK-994. TAK-994 is being tested to find a safe and well-tolerated dose in healthy participants (non-Japanese and Japanese) and healthy elderly participants. The study will enroll up to approximately 160 healthy participants. The study consists of 6 parts and up to 20 cohorts as mentioned below.
- TAK-994: Part A: Single-rising dose (SRD) design to assess the safety, tolerability, and PK of TAK-994 and effect of food on the PK of the TAK-994
- TAK-994: Part B: MRD design to assess the safety, tolerability, PK and PD of TAK-994
- TAK-994: Part C: MRD design to assess the safety, tolerability, PK and PD of TAK-994 and also central nervous system penetration relative to plasma concentrations of TAK-994
- TAK-994: Part D: MRD design to assess the safety, tolerability, PK and PD of TAK-994 for HE participants
- TAK-994: Part E: SRD and MRD design to assess the safety, tolerability, PK and PD of TAK-994 for Japanese origin participants
- TAK-994: Part F (Optional Cohort): Nonrandomized design to assess orexin (OX) levels in the cerebrospinal fluid (CSF) of untreated healthy adult participants.
Participants in each cohort will be randomized to receive treatment with TAK-994 or matching placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need). Participants in optional Part F will receive no study drug.
This multi-center trial will be conducted in the United States. The overall duration of the study is approximately 10 months. Participants will be followed up for 7 days after the last dose of study drug for a follow-up assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States, 91206
- PAREXEL International
-
-
Utah
-
Salt Lake City, Utah, United States, 84125
- PRA Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Be normotensive, with no history of hypertension or use of antihypertensive medication. Blood pressure (BP) must be less than (<) 140 millimeter of mercury (mmHg) (systolic) and <90 mmHg (diastolic).
Healthy Adult and Elderly Participants (Parts A through D and Part F)
Must have a body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to (<=) 30.0 kilogram per square meter (kg/m^2) at the screening visit (non-Japanese only).
Healthy Adult Participants (Parts A, B, C, and F)
- Must be aged 18 to 55 years, inclusive, at the screening visit.
Must have a body weight >=50 kilogram (kg) at the screening visit.
HE Participants (Part D)
- Must be aged >=65 years, inclusive, at the time of informed consent.
Must have a body weight >=40 kg at the screening visit.
Healthy Japanese Adult Participants (Part E)
- Must be aged 18 to 55 years, inclusive, at the screening visit.
- Must have a BMI >=18.0 and <=26.0 kg/m^2 at the screening visit.
- Must have been born in Japan to a Japanese mother and father and have maternal and paternal Japanese grandparents.
- Must have not been away from Japan for more than 10 years at the screening visit.
- In the opinion of the investigator, must have a lifestyle that has not changed significantly since relocation from Japan.
Exclusion Criteria:
- Has a known hypersensitivity to any component of the formulation of TAK-994 or related compounds.
- Has a risk of suicide according to endorsement of Item 4 or 5 of the screening/baseline visit Columbia Suicide Severity Rating Scale (C-SSRS) or has made a suicide attempt in the previous 6 months.
- Has a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia. Participant who have history of major depressive disorder (MDD) may be included, but participants who have current active MDD or who have had active MDD in the past 6 months are excluded.
- Has a clinically significant history of head injury or head trauma.
- Has a history of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous malformation.
- Screening electrocardiogram (ECG) reveals a QT interval with the Fridericia's correction method (QTcF) greater than (>) 450 millisecond (ms) (men) or >470 ms (women).
Has a resting heart rate outside of the range of 45 to 100 beats per minute, confirmed on repeat testing within a maximum of 30 minutes).
Healthy Non-Japanese Adult Participants (Part C and Part F)
- Has undergone CSF collection within 30 days before check-in (Day -2 [Part C] or Day -1 [Part F]).
- Has a known hypersensitivity to anesthesia or its derivatives used during CSF collection or to any medication used to prepare the area of lumbar puncture.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAK-994: Part A
TAK-994 tablet or matching placebo, orally, once on Day 1 to healthy non-Japanese participants.
Sentinel dosing will be done in the first 2 cohorts of Part A (Cohorts A1 and A2 [fasted and fed dosing conditions]).
Dose escalation in Cohorts A2 to A6 will be based on emerging safety, tolerability, and PK (pharmacokinetic) data from previous cohorts.
|
TAK-994 tablets.
TAK-994 placebo-matching tablets.
|
Experimental: TAK-994: Part B
TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese participants.
Dose escalation will be based on review of the emerging safety, PK, and PD (pharmacodynamic) data from Part A. Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
|
TAK-994 tablets.
TAK-994 placebo-matching tablets.
|
Experimental: TAK-994: Part C
TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 7 to healthy non-Japanese participants.
Dose will be determined based on previous multiple-rising dose (MRD) cohorts.
|
TAK-994 tablets.
TAK-994 placebo-matching tablets.
|
Experimental: TAK-994: Part D
TAK-994 tablet or matching placebo, orally, once daily or twice daily from Day 1 to Day 14 to healthy non-Japanese elderly participants.
Dose will be determined based on previous MRD cohorts.
Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
|
TAK-994 tablets.
TAK-994 placebo-matching tablets.
|
Experimental: TAK-994: Part E
TAK-994 tablet or matching placebo, orally, once or twice on Day 1, followed by a washout period of 2 days and on Day 4 and continue to Day 17 to healthy Japanese participants.
Dose will be determined based on previous MRD cohorts.
Fixed-dose titration regimens may also be evaluated based on review of the emerging safety, PK, and tolerability data from previous cohorts.
|
TAK-994 tablets.
TAK-994 placebo-matching tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)
Time Frame: Baseline up to Day 26
|
Baseline up to Day 26
|
Number of Participants With at Least one Markedly Abnormal Laboratory Value
Time Frame: Baseline up to Day 26
|
Baseline up to Day 26
|
Number of Participants With at Least one Markedly Abnormal Laboratory Value for Vital Signs
Time Frame: Baseline up to Day 26
|
Baseline up to Day 26
|
Number of Participants With at Least one Markedly Abnormal Laboratory Value for Electrocardiogram (ECG)
Time Frame: Baseline up to Day 26
|
Baseline up to Day 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax: Maximum Observed Plasma Concentration for TAK-994
Time Frame: Day 1 (Parts A-E), Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 1 (Parts A-E), Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-994
Time Frame: Day 1 (Parts A-E), Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 1 (Parts A-E), Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-994
Time Frame: Day 1 (Parts A-E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 1 (Parts A-E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-994
Time Frame: Day 1 (Parts A-E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 1 (Parts A-E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
T1/2z: Terminal Disposition Phase Half-life for TAK-994
Time Frame: Day 1 (Parts A-E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 1 (Parts A-E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
CLR: Renal Clearance for TAK-994
Time Frame: Day 1 (Parts A, B, D and E), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 1 (Parts A, B, D and E), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to tau over Dosing Interval for TAK-994
Time Frame: Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Part C: Ratio of the Cerebrospinal Fluid (CSF) to plasma AUC From time 0 to 24 hours for TAK-994
Time Frame: Day 7 (Part C) Pre-dose and at multiple time points (up to 24 hours) post-dose
|
Day 7 (Part C) Pre-dose and at multiple time points (up to 24 hours) post-dose
|
Rac(AUC): Accumulation ratio based on AUCτ for TAK-994
Time Frame: Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Day 7 (Part C), Day 14 (Parts B and D), Day 17 (Part E) pre-dose and at multiple time points (up to 72 hours) post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TAK-994-1001
- U1111-1230-8479 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbNot yet recruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on TAK-994
-
TakedaCompletedHealthy VolunteersUnited States
-
TakedaCompleted
-
TakedaTerminatedNarcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
-
TakedaCompleted
-
TakedaTerminatedNarcolepsy Type 1 (NT 1)United States, Italy, Finland, Canada, Hungary, Czechia, France, Japan, Korea, Republic of, Spain
-
Recursion Pharmaceuticals Inc.Active, not recruitingCerebral Cavernous MalformationUnited States
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
TakedaWithdrawn